REG - Eden Research plc - Director/PDMR Shareholding

Eden ResearchAnnouncement

28/07/2021 14:55

RNS Number : 7997G
  
Eden Research plc
  
28 July 2021
  
 

 
28 July 2021
 
Eden Research plc
 
("Eden" or "Company")
 
Director/PDMR Shareholding
 
Eden Research plc (AIM: EDEN), the AIM-quoted company focused on sustainable biopesticides and plastic-free formulation technology for use in global crop protection, animal health and consumer products industries, announces that Sean Smith, CEO, has purchased 180,000 shares in Eden at a price of £0.10 per share.
 
Following the transaction outlined above, Mr. Smith's interest in the share capital of the Company is 911,039 Ordinary Shares representing 0.24 per cent. of the Company's issued share capital.  
 
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
 
 
 
 
 
 
 
 
 
 
 
For further information contact:



 
Eden Research plc


www.edenresearch.com




Sean Smith

Alex Abrey


01285 359 555




 
Cenkos Securities plc (Nominated advisor and broker)








Giles Balleny / Camilla Hume/ Mark Connelly  (corporate finance)

Michael Johnson (sales)


020 7397 8900




 
Hawthorn Advisors (Financial PR)








Lorna Cobbett / Victoria Ainsworth


eden@hawthornadvisors.com



 
 
 
 
 
 
 
 
 
 
 
 
 
 
 



1
 


Details of the person discharging managerial responsibilities / person closely associated
 




a)
 


Name


Sean Smith




2
 


Reason for the notification
 




a)
 


Position/status
 


Chief Executive Officer




b)
 


Initial notification /Amendment
 


Initial Notification




3
 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 




a)
 


Name
 


Eden Research plc




b)
 


LEI
 


213800ZWTYTVQQSM3J85




4
 


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted




a)
 


Description of the financial instrument, type of instrument
Identification code
 


Ordinary shares of 1 pence each
 
 
GB0001646941




b)
 


Nature of the transaction
 


Purchase of Ordinary Shares 
 




c)
 


Price(s) and volume(s)
 





Price(s)
 


Volume(s)




10.00p


180,000








d)
 


Aggregated information
- Aggregated volume
- Price
 


 
 
N/A




e)
 


Date of the transaction
 


28 July 2021




f)
 


Place of the transaction
 


LSE, AIM Market (XLON)
 



 
 
 
 
 
 
 
 
 
 
 
 
Notes to Editors:
 
Eden Research is an AIM quoted company that develops and supplies breakthrough biopesticide products and natural, plastic-free microencapsulation technologies to the global crop protection, animal health and consumer products industries.
 
Eden's Sustaine® encapsulation technology is used to harness the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with both natural and synthetic compounds to enhance their performance and ease-of-use. Sustaine microcapsules are naturally derived, plastic-free, biodegradable micro-spheres derived from yeast extract. It is one of the only viable, proven and immediately registerable solutions to the microplastics problem in formulations requiring encapsulation.
 
Eden has numerous patents and a pipeline of products at differing stages of development targeting specific areas of the global agrochemicals industry. Eden was admitted to trading on AIM in May 2012.
 
For more information about Eden, please visit: www.edenresearch.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
DSHSEFFDAEFSEIW